Pharmaceutical industry – Page 30
-
BusinessPharmaceutical industry roundup of 2016
Controversial approvals and price clashes characterised 2016 in pharma
-
BusinessEndo drops opioid painkiller rights and cuts US sales force
375 staff to go as Endo says its established pain drugs ‘no longer require field promotion’
-
BusinessBoehringer Ingelheim sheds more jobs in the US
Over 240 staff to go as company refocuses on immuno-oncology
-
-
Business£90m fine for Pfizer and Flynn Pharma over excessive drug pricing
Markets watchdog imposes record fine for breaches of competition law
-
BusinessPfizer pulls back on UK and Ireland facilities
€400 million manufacturing plant expansion cancelled and two facilities to close
-
BusinessFormer Valeant and Philidor executives arrested for fraud
Prosecutors allege the men masterminded a kickback scheme between Valeant and the speciality pharmacy
-
OpinionHow much does fashion influence chemists?
Is that new reaction the next Nobel-worthy breakthrough, or just a flash in the pan?
-
OpinionRestarting the mental health pipeline
The lack of UK investment in new drugs for mental health disorders is a problem – but the tide may be about to turn
-
CareersThe trials and tribulations of drug discovery
The many pitfalls medicinal chemists face when creating a new drug
-
FeaturePersonalised skincare
Nina Notman explores some of the latest scientific approaches skincare companies are using in the quest to develop high-earning anti-ageing cosmetics
-
OpinionRegulatory tightropes
When lobbying and marketing clash with scientific evidence, regulators walk a fine line
-
OpinionPutting chemistry back in biology
The chemical nature of biomolecular interactions can no longer be ignored
-
BusinessA match made in medicine
Technology companies have begun to turn their resources towards health research. Is it just hype or can big tech bring something new?
-
BusinessAstraZeneca sheds multiple drugs
Spate of licensing deals for non-core products as firm further tightens R&D focus
-
NewsPfizer launches new biosimilar drug in US
Autoimmune disease treatment becomes only the second biosimilar to be approved by the FDA
-
PodcastGabapentin
Louise Crane documents the rise and fall of Gabapentin – from ‘wonder drug’ to illicit substance in just 50 years
-
BusinessTroubled Theranos abandons clinical testing
Seeking to salvage some value, once-admired blood analysis firm lays off 40% of staff
-
BusinessNovartis consolidates research sites
Company will close research sites in China and Switzerland, and relocate another from Singapore to US
-
BusinessIndia’s Intas bags UK and Irish generics
Teva sheds former Actavis business to satisfy competition requirements of its Allergan generics takeover